Key result
Y041-1672 effectively inhibits PEDV 3CL protease to reduce viral replication in vitro.
Why the study?
PEDV causes high mortality in suckling piglets, and its essential 3C-like protease is a critical target for antiviral inhibitor development.
Answers are grounded in this paper and cite their sources.
Y041-1672 is a promising scaffold molecule for developing antiviral drugs against porcine epidemic diarrhea virus by targeting its 3CL protease.
Porcine epidemic diarrhea (PED), caused by porcine epidemic diarrhea virus (PEDV), is a highly contagious gastrointestinal disease characterized by vomiting, diarrhea, and dehydration, with mortality rates approaching 100% among suckling piglets. The PEDV 3C-like protease (3CLpro) is essential for viral replication and regarded as a critical target for antiviral inhibitor development. In this study, we aimed to identify small-molecule inhibitors of PEDV by targeting 3CLpro. Virtual screening of 1.6 million compounds from the ChemDiv library identified four potential candidates. Molecular dynamics simulations, (RMSD, RMSF, Rg) revealed enhanced structural stability of the compound-protease complexes compared to the monomeric enzyme. All compounds had low cytotoxicity in Vero cells (CC 50 > 200 μM). Fluorescence resonance energy transfer-based assays demonstrated dose-dependent inhibitory activity of the compounds against 3CLpro. Among the candidates, compound F366-0161 exhibited the weakest inhibition, with an IC 50 value of 151.5 μM. Two analogues, 3238-0395 (IC 50 of 121.4 μM) and L878-0493 (IC 50 of 123.6 μM), exhibited moderately enhanced activity. Y041-1672 was identified as the most effective inhibitor, with an IC 50 of 86.48 μM. In viral replication inhibition assays, Y041-1672 reduced PEDV replication, with an EC 50 of 17.97 μM and a selectivity index (SI) of 15.5 (CC 50 /EC 50 ). These results were validated by RT-qPCR, plaque assays, immunofluorescence, and Western blot analyses. In vitro validation confirmed Y041-1672 as the optimal antiviral candidate, and time-of-addition experiments indicated that inhibition primarily occurred during viral replication. This study identifies scaffold molecules for PEDV antiviral drug development, providing strategic insights for PED treatment.
No takes yet. Share an insight, caveat, or question.
Tian et al. (2025) studied Porcine epidemic diarrhea virus (PEDV). Y041-1672 and other small-molecule inhibitors was evaluated on Inhibition of PEDV 3CLpro and viral replication. Virtual screening and in vitro assays identified Y041-1672 as an effective inhibitor of PEDV 3CL protease, reducing viral replication with an EC50 of 17.97 μM.
Synapse has enriched 10 related papers. Consider them for comparative context: